Expression and clinical significance of SLC5A5 gene of sodium/iodide symporter in thyroid carcinoma based on the biological information database
10.3760/cma.j.issn.2095-2848.2019.11.007
- VernacularTitle: 基于生物信息数据库分析钠碘同向转运体编码基因SLC5A5在甲状腺癌中的表达及临床意义
- Author:
Junyu TONG
1
;
Tingting QIAO
;
Zhongwei LYU
;
Dan LI
Author Information
1. Department of Nuclear Medicine, Tenth People′s Hospital of Tongji University, Shanghai 200072, China
- Publication Type:Journal Article
- Keywords:
Thyroid neoplasms;
Sodium/iodide symporter;
Gene expression;
Databases, nucleic acid
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2019;39(11):670-674
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the expression and clinical significance of solute carrier family 5 member 5 (SLC5A5), the coding gene of sodium/iodide symporter (NIS), in thyroid carcinoma.
Methods:The messenger RNA (mRNA) expression of SLC5A5 in thyroid carcinoma and normal thyroid tissues from The Cancer Genome Atlas (TCGA) was compared using independent-sample t test and results were shown in one scatter plot. The relation between clinical features of thyroid carcinoma and the changes of SLC5A5 mRNA was analyzed on LinkedOmics using Kruskal-Wallis test or Wilcoxon test.
Results:Data from TCGA showed that the SLC5A5 mRNA expression in thyroid carcinoma (1.419±0.049) was significantly reduced compared with that in normal thyroid tissues (3.301±0.087; t=12.66, P<0.01). The expression of SLC5A5 mRNA in thyroid carcinoma is affected by ethnicity (χ2=0.300, P<0.05). Moreover, the expression of SLC5A5 mRNA were decreased with the increase of pathologic grading (Ⅰ, Ⅱ, Ⅲ, Ⅳ) and T, N, M stages (χ2 values: 0.114, 0.215, z values: -0.345, -0.102, all P<0.05).
Conclusions:The expression level of SLC5A5 mRNA is associated with clinical characteristic of thyroid carcinoma. SLC5A5 mRNA has the potential to become one candidate biomarker to assess disease and predict the development of thyroid carcinoma.
